Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2,000
Single User License Price INR 135
Corporate User License Price USD 6,000
Corporate User License Price INR 405
Site License Price USD 4,000
Site License Price INR 270
Request a Quote

Report Title

Small-Cell Lung Cancer - Pipeline Review, H1 2018

Quote Request for License Type
License Type Price  
Single User License USD 2,000
Site License USD 4,000
Enterprise Wide License USD 6,000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Small-Cell Lung Cancer - Pipeline Review, H1 2018


Quote Request for License Type
License Type Price  
Single User License USD 2,000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Small-Cell Lung Cancer - Pipeline Review, H1 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Small-Cell Lung Cancer - Pipeline Review, H1 2018



Executive Summary

Small-Cell Lung Cancer - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2018, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.

Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 47, 33, 2, 36 and 6 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively.

Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

Introduction 7

Small-Cell Lung Cancer - Overview 8

Small-Cell Lung Cancer - Therapeutics Development 9

Small-Cell Lung Cancer - Therapeutics Assessment 26

Small-Cell Lung Cancer - Companies Involved in Therapeutics Development 40

Small-Cell Lung Cancer - Drug Profiles 76

Small-Cell Lung Cancer - Dormant Projects 779

Small-Cell Lung Cancer - Discontinued Products 785

Small-Cell Lung Cancer - Product Development Milestones 787

Appendix 795

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Small-Cell Lung Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

List of Tables

Number of Products under Development for Small-Cell Lung Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Small-Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018

Small-Cell Lung Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Amgen Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Aposense Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Aprea AB, H1 2018

Small-Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2018

Small-Cell Lung Cancer - Pipeline by Autolus Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2018

Small-Cell Lung Cancer - Pipeline by Bayer AG, H1 2018

Small-Cell Lung Cancer - Pipeline by BeiGene Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Beta Pharma Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by BioLineRx Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Bionomics Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

Small-Cell Lung Cancer - Pipeline by Celgene Corp, H1 2018

Small-Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Checkpoint Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Cytori Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2018

Small-Cell Lung Cancer - Pipeline by Eli Lilly and Co, H1 2018

Small-Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018

Small-Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H1 2018

Small-Cell Lung Cancer - Pipeline by Immunomedics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Incyte Corp, H1 2018

Small-Cell Lung Cancer - Pipeline by Ipsen SA, H1 2018

Small-Cell Lung Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2018

Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by MedImmune LLC, H1 2018

Small-Cell Lung Cancer - Pipeline by Merck & Co Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Merck KGaA, H1 2018

Small-Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Moderna Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Mologen AG, H1 2018

Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2018

Small-Cell Lung Cancer - Pipeline by NewLink Genetics Corp, H1 2018

Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Novartis AG, H1 2018

Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Pfizer Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Pharma Mar SA, H1 2018

Small-Cell Lung Cancer - Pipeline by Plexxikon Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Rafael Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Recombio SL, H1 2018

Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Sierra Oncology Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Sunshine Biopharma Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AbbVie Inc

Advenchen Laboratories LLC

Aeglea BioTherapeutics Inc

Amgen Inc

Andarix Pharmaceuticals Inc

Aposense Ltd

Aprea AB

Ascentage Pharma Group Corp Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Autolus Ltd

AVEO Pharmaceuticals Inc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beta Pharma Inc

BeyondSpring Pharmaceuticals Inc

BioLineRx Ltd

Bionomics Ltd

Bristol-Myers Squibb Co

Celgene Corp

Celldex Therapeutics Inc

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Cotinga Pharmaceuticals Inc

Cytori Therapeutics Inc

Double Bond Pharmaceutical International AB

Eli Lilly and Co

F. Hoffmann-La Roche Ltd

G1 Therapeutics Inc

GlaxoSmithKline Plc

Hanmi Pharmaceuticals Co Ltd

Horizon Pharma Plc

Immunomedics Inc

Incyte Corp

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Karyopharm Therapeutics Inc

MabVax Therapeutics Holdings Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Mologen AG

Nektar Therapeutics

NewLink Genetics Corp

Nippon Kayaku Co Ltd

Novartis AG

Ono Pharmaceutical Co Ltd

Oxford BioTherapeutics Ltd

Pfizer Inc

Pharma Mar SA

Plexxikon Inc

Rafael Pharmaceuticals Inc

Recombio SL

Rexahn Pharmaceuticals Inc

Sierra Oncology Inc

Sun Pharma Advanced Research Company Ltd

Sunshine Biopharma Inc

Syros Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Tarveda Therapeutics Inc

Tesaro Inc

Teva Pharmaceutical Industries Ltd

Trillium Therapeutics Inc

Trovagene Inc

United Therapeutics Corp

Verastem Inc

Xencor Inc

Zensun (Shanghai) Sci & Tech Co Ltd

ZIOPHARM Oncology Inc

Small-Cell Lung Cancer Therapeutic Products under Development, Key Players in Small-Cell Lung Cancer Therapeutics, Small-Cell Lung Cancer Pipeline Overview, Small-Cell Lung Cancer Pipeline, Small-Cell Lung Cancer Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand